Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Calibration-free odds type ...

What Are the Real Pros of Real-Time PROs (Patient-Reported Outcomes)? The following represents disclosure information provided by the author of this manuscript. All relationships are considered ...

Tailored Approaches in the Treatment of Patients With Colorectal Cancer Harboring Tropomyosin Receptor Kinase Fusion and Microsatellite Instability-High: A Case Report and Literature Review The ...

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care ...

Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...

The improvement in measures of well-being over the past decade illustrates that progress is possible and should encourage the cancer care community to continue efforts to optimize oncology training.

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas Larotrectinib is a ...

Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma. Pembro: pembrolizumab, mo: month. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

A protein-based blood panel test for the early detection of colorectal cancer and advanced neoplasia. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). Single-cycle neoadjuvant ...

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.